Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations

Bruton’s tyrosine kinase (BTK) inhibitors have dramatically changed the treatment of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL). Ibrutinib, acalabrutinib, and zanubrutinib are Food and Drug Administration (FDA)-approved BTK inhibitors that have all demonstrated progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Lovell, Alexandra R., Jammal, Nadya, Bose, Prithviraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373150/
https://www.ncbi.nlm.nih.gov/pubmed/35966045
http://dx.doi.org/10.1177/20406207221116577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373150/
https://www.ncbi.nlm.nih.gov/pubmed/35966045
http://dx.doi.org/10.1177/20406207221116577

Ejemplares similares